Analysis Of Clinical Efficacy Of Induction Therapy Of Mesenchymal Stem Cells In Renal Transplantation Patients

Objective:To observe the clinical effects of umbilical cord mesenchymal stem cells compared with basiliximab in inducing immune tolerance formation in kidney transplantation,promoting the recovery of renal function after kidney transplantation,and reducing post-transplant complications.Methods:By consulting the medical records and the follow-up book of kidney transplant patients in our department,according to the enrollment criteria,169 eligible kidney transplant patients were strictly screened from January 2012 to December 2016,and these patients were divided into hU infusions-MSCs experimental group(74 cases)and control group(95 cases)using basiliximab.Mesenchymal stem cells were collected from the umbilical cord of healthy newborns born in the delivery room of our hospital(after testing,HBV infection,HCV infection,HIV infection,TP-SX infection,CMV infection are all negative results),under aseptic conditions.Obtained after separation,cultivation,and amplification.In the hU-MSCs group,hU-MSCs were infused intravenously during the operation and 14 days after the operation.In the control group,basiliximab was used for antibody induction therapy 2 hours before the operation and the 4th day after the operation.Observation of hU-MSCs and the control group postoperative renal function indicators,the occurrence of acute rejection,postoperative immunosuppressive drug use and blood concentration,and the incidence of related postoperative complications.The follow-up time was 1 year.Results:The amount of drug used,blood drug concentration and the incidence of related postoperative complications,the follow-up time was 1 year.Results:There was no significant difference in basic data between the hU-MSCs group and the basiliximab group before surgery(P>0.05).Within 6 months and 12 months after the operation,the incidence of AR in the hU-MSC s group was lower than that in the basiliximab group,but the difference was not statistically significant;within 12 months after the operation,hUMSCs The incidence of DGF in the group was lower than that in the basiliximab group.and the difference was statistically significant(P=0.034);the estimated glomerular filtration rate(eGFR)of the hU-MSCs group at 7 and 14 days after surgery was higher than that in the baliximab group In the cilimab group(P<0.05),the difference was statistically significant.There was no statistically significant difference in eGFR between the two groups at other data collection points;the applied dose of CsA in the hU-MSCs group was low at 60d,90d,and 180d postoperatively In the basiliximab group,there was a statistically significant difference(P<0.05);the dose of FK506 in the hU-MSCs group was lower than that of basiliximab at 7d,14d,30d,60d,and 180d after surgery Group,there is a statistically significant difference(P<0.05);the applied dose of Pred in the hUMSCs group is lower than that of the basiliximab group at 60d and 90d postoperatively,showing a statistically significant difference(P<0.05));The incidence of abnormal liver function in the hU-MSCs group within 1 year after surgery was 8.11%,which was lower than the 18.95%of basiliximab group.The difference was statistically significant(P<0.05).There was no statistically significant difference in the incidence of postoperative lung infection between the hU-MSCs group and the basiliximab group(P>0.05).Conclusion:MSCs can reduce the occurrence of acute rejection after renal transplantation,induce the formation of immune tolerance,promote the early recovery of transplanted kidney function,reduce the use of postoperative immunosuppressants,and do not increase the incidence of postoperative complications.